UnknownNot Applicable

Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma

100 participantsStarted 2020-01-01

Plain-language summary

Multiple myeloma (MM) is blood disorder characterized by the detection of a monoclonal paraprotein in serum or urine, which is often associated with the presence of clonal plasma cells (PCs) mainly in the bone marrow (BM) .The zinc-finger protein 217 (ZNF217) is an oncogenic protein that plays deleterious functions in various human cancers. The ZNF217 gene is located at the 20q13 chromosomal region, which is frequently amplified in human tumors .

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Newly diagnosed multiple myeloma patients, who fulfill the WHO criteria of myeloma diagnosis. Exclusion Criteria: * Patients with any other type of malignant or benign tumors should be excluded from our study.

What they're measuring

zinc-finger protein gene 217 in myeloma patients

Timeframe: 2 years

Trial details

NCT IDNCT04212858

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-01

View on ClinicalTrials.gov More Multiple Myeloma trials